One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
May 18, 2026 06:01 AM EDTUpdated 10:50 AM
PharmaFDA+
AstraZeneca's blood pressure pill approved, but competition could be around the corner
Elizabeth Cairns
Senior biopharma journalist
AstraZeneca picks up FDA approval for hypertension drug
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
FDA approves AstraZeneca’s new kind of hypertension drug
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
AstraZeneca CEO Pascal Soriot aims for $80B annual sales by 2030; company on track with $58.7B in 2025, despite future loss of…
The China question, FDA leadership shakeups, and other biotech news from The Readout
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that…
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb…
Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s…
